Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 699,830 |
|
|||||
| News | (1) | ||||||
| Day High | 8.64 | Low High |
|||||
| Day Low | 8.26 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Zymeworks Inc | ZYME | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.32 | 3.84% | 8.65 | 16:50:33 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.31 | 8.26 | 8.64 | 8.58 | 8.33 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,023 | 699,830 | $ 8.50 | $ 5,945,167 | - | 6.015 - 13.14 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:35:54 | priorref | 291,800 | $ 8.58 | USD |
Zymeworks Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 453.75M | 70.57M | - | 76.3M | -118.67M | -1.68 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Zymeworks News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ZYME Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.76 | 8.93 | 7.97 | 8.33 | 590,308 | -0.11 | -1.26% |
| 1 Month | 9.595 | 9.98 | 7.97 | 8.93 | 584,264 | -0.945 | -9.85% |
| 3 Months | 10.87 | 13.14 | 7.97 | 10.48 | 589,715 | -2.22 | -20.42% |
| 6 Months | 6.69 | 13.14 | 6.69 | 10.00 | 525,974 | 1.96 | 29.30% |
| 1 Year | 8.45 | 13.14 | 6.015 | 8.94 | 516,225 | 0.20 | 2.37% |
| 3 Years | 6.38 | 13.14 | 6.015 | 8.77 | 620,497 | 2.27 | 35.58% |
| 5 Years | 6.38 | 13.14 | 6.015 | 8.77 | 620,497 | 2.27 | 35.58% |
Zymeworks Description
| Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
